Literature DB >> 15515017

Cervical cancer in the Netherlands 1989-1998: Decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women.

Saskia Bulk1, Otto Visser, Lawrence Rozendaal, René H M Verheijen, Chris J L M Meijer.   

Abstract

Cervical cancer is a preventable disease, occurring in relatively young women. In the Netherlands, population-based cervical screening aims at women aged 30-60 years. We performed a population-based study of the incidence of invasive cervical cancer in the Netherlands to evaluate trends, with emphasis on age at time of diagnosis. Histologic diagnosis was retrieved from the Netherlands Cancer Registry for all women residing in the Netherlands with invasive cervical cancer between January 1, 1989, and December 31, 1998. In this 10-year period, the incidence rate of squamous cell carcinoma decreased significantly from 7.1/100,000 to 6.1/100,000 (p < 0.001), with the greatest decrease in women aged 60-74 (-5.5%). While the overall incidence rate of adenocarcinoma remained stable, it increased in women aged 15-29 (+15.8%) and in women aged 30-44 (+2.5%), though the number of cases was small. For squamous cell carcinoma, the incidence of stage II at diagnosis decreased most (-2.7%). There was no change in stage at diagnosis for adenocarcinoma. Most cases of cervical cancer, 60.5%, were detected between ages 30 and 60 years, i.e., the Dutch screening age interval. Cervical cancer in women below age 30 contributed 5.0% to the total incidence, with 3.0% occurring between ages 27 and 29. Thus, screening for cervical cancer in the Netherlands is associated with a decrease in the incidence of squamous cell carcinoma and adenocarcinoma incidence appears to be increasing in younger women. (c) 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2005        PMID: 15515017     DOI: 10.1002/ijc.20678

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  29 in total

1.  High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brush.

Authors:  Antoinette A T P Brink; Chris J L M Meijer; Maarten A H M Wiegerinck; Thedoor E Nieboer; Roy F P M Kruitwagen; Folkert van Kemenade; Nathalie Fransen Daalmeijer; Albertus T Hesselink; Johannes Berkhof; Peter J F Snijders
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

2.  Relationship between hWAPL polymorphisms and cervical cancer susceptibility.

Authors:  Li Li; Gen-Long Jiao; Shuang Qin; Qing Xiao
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

3.  Long-term costs of introducing HPV-DNA post-treatment surveillance to national cervical cancer screening in Ireland.

Authors:  Maria Agapova; Andrea Duignan; Alan Smith; Ciaran O'Neill; Anirban Basu
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2015-09-17       Impact factor: 2.217

4.  Human papillomavirus vaccine uptake, knowledge and attitude among 10th grade students in Berlin, Germany, 2010.

Authors:  Petra Stöcker; Manuel Dehnert; Melanie Schuster; Ole Wichmann; Yvonne Deleré
Journal:  Hum Vaccin Immunother       Date:  2012-09-20       Impact factor: 3.452

5.  The nurse's role in the prevention of cervical cancer among underserved and minority populations.

Authors:  Norma Martinez Rogers; Adelita G Cantu
Journal:  J Community Health       Date:  2009-04

6.  A population-based evaluation of cervical screening in the United States: 2008-2011.

Authors:  Jack Cuzick; Orrin Myers; William C Hunt; Michael Robertson; Nancy E Joste; Philip E Castle; Vicki B Benard; Cosette M Wheeler
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-12-03       Impact factor: 4.254

7.  The evaluation of older patients with cervical cancer.

Authors:  Ying Gao; Jin-lu Ma; Fei Gao; Li-ping Song
Journal:  Clin Interv Aging       Date:  2013-06-25       Impact factor: 4.458

8.  Trends in breast, ovarian and cervical cancer incidence in Mumbai, India over a 30-year period, 1976-2005: an age-period-cohort analysis.

Authors:  P K Dhillon; B B Yeole; R Dikshit; A P Kurkure; F Bray
Journal:  Br J Cancer       Date:  2011-08-09       Impact factor: 7.640

9.  Cervical cancer in the screening era: who fell victim in spite of successful screening programs?

Authors:  B Folke Pettersson; Kristina Hellman; Roxane Vaziri; Sonia Andersson; Ann-Cathrin Hellström
Journal:  J Gynecol Oncol       Date:  2011-06-30       Impact factor: 4.401

10.  HLA-E expression in cervical adenocarcinomas: association with improved long-term survival.

Authors:  Vivian M Spaans; Alexander A W Peters; Gert Jan Fleuren; Ekaterina S Jordanova
Journal:  J Transl Med       Date:  2012-09-04       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.